Payment overview · 2025
General Payments
$417.27
21 reported records · 11 companies
Healthcare provider profile · identity verified
Steven Mark Manning, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WILLIAMSTON, NC · NPI 1932367521
Verified facts
What the public records show
CMS Open Payments records show Steven Mark Manning, M.D. received $417.27 in general payments during 2025 across 21 reported records.
Boston Scientific Corporation accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.62 | 14.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.53 | 12.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.96 | 12.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.58 | 11.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.03 | 11.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.45 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.04 | 9.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.54 | 7.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.68 | 5.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.25 | 4.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.59 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.27 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $58.62 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.53 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.96 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.45 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.25 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
57 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 406 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 333 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 68 |
| Omeprazole | Omeprazole | 313 | 56 |
| Lisinopril | Lisinopril | 274 | 48 |
| Losartan Potassium | Losartan Potassium | 274 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 40 |
| Gabapentin | Gabapentin | 247 | 43 |
| Metformin Hcl Er | Metformin Hcl | 217 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 28 |
| Prednisone | Prednisone | 149 | 80 |
| Furosemide | Furosemide | 131 | 35 |
| Metformin Hcl | Metformin Hcl | 108 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 22 |
| Eliquis | Apixaban | 96 | 13 |
| Ozempic | Semaglutide | 93 | 17 |
| Sertraline Hcl | Sertraline Hcl | 93 | 17 |
| Tramadol Hcl | Tramadol Hcl | 91 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 15 |
| Jardiance | Empagliflozin | 89 | 13 |
| Finasteride | Finasteride | 87 | 14 |
| Lorazepam | Lorazepam | 85 | 13 |
| Alprazolam | Alprazolam | 82 | 14 |
| Myrbetriq | Mirabegron | 82 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | suppressed |
| Ezetimibe | Ezetimibe | 71 | 15 |
| Methocarbamol | Methocarbamol | 71 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 32 |
| Potassium Chloride | Potassium Chloride | 67 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 14 |
| Allopurinol | Allopurinol | 61 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 57 | 57 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 11 |
| Celecoxib | Celecoxib | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 38 |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 14 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Sucralfate | Sucralfate | 48 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 33 |
| Carvedilol | Carvedilol | 46 | 11 |
| Atenolol | Atenolol | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | 14 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 16 |
| Glipizide | Glipizide | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Famotidine | Famotidine | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 35 | 35 |
| Cefdinir | Cefdinir | 35 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 19 |
| Naproxen | Naproxen | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 13 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.27 · 21 records | Boston Scientific Corporation | Dexcom G6 Transmitter, ELIQUIS, FANAPT, GEMTESA, HETLIOZ, Korlym, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VOQUEZNA, VRAYLAR, WATCHMAN Access System, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error